How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?

Dholaria, Bhagirathbhai; Savani, Bipin N

Dholaria, Bhagirathbhai; Savani, Bipin N.

Dholaria B; Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Savani BN; Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.

Br J Haematol ; 189(2): 239-240, 2020 Apr.

Article in English | MEDLINE | ID: covidwho-8794

Subject(s)

Betacoronavirus; Coronavirus Infections; Hematopoietic Stem Cell Transplantation; Pandemics; Pneumonia, Viral; Blood Donors; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coronavirus Infections/diagnosis; Coronavirus Infections/prevention & control; Coronavirus Infections/transmission; Hematopoietic Stem Cell Transplantation/adverse effects; Humans; Immunocompromised Host; Pandemics/prevention & control; Pneumonia, Viral/prevention & control; Pneumonia, Viral/transmission; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Hematopoietic Stem Cell Transplantation / Pandemics / Betacoronavirus Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Br J Haematol Year: 2020 Document Type: Article Affiliation country: Bjh.16597

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google